US Judge Rules Biden-Era Restrictions on Abortion Pill Mifepristone Were Unlawful
A federal judge in Virginia has ruled that parts of the Biden administration's restrictions on prescribing the abortion medication mifepristone were unlawful, saying the U.S. Food and Drug Administration (FDA) failed to adequately justify requiring doctors and pharmacies to obtain special certification before prescribing the drug.
The decision adds to the ongoing legal battles over abortion access in the United States, where mifepristone has remained at the center of national policy and court disputes since the Supreme Court overturned Roe v. Wade in 2022.
Judge Questions FDA Certification Requirements
U.S. District Judge Robert Ballou ruled that the FDA did not sufficiently explain why the certification requirements introduced in 2023 were necessary after the agency had repeatedly concluded that mifepristone is safe and effective.
The ruling came in response to a lawsuit filed by three abortion providers challenging the restrictions.
Judge Ballou said federal law allows the court to require the FDA to reconsider the rule but does not permit him to immediately invalidate it.
Legal Challenge Could Continue
While the judge declined to strike down the certification requirements at this stage, he indicated he could consider additional claims later in the case, including allegations that the rule violates constitutional protections.
The FDA, which is currently reviewing mifepristone policies under the Trump administration, did not immediately comment on the ruling.
Mifepristone Remains Central to Abortion Debate
Mifepristone, used as part of a two-drug medication abortion regimen, accounts for more than 60% of abortions in the United States.
The FDA first approved the medication in 2000 and has expanded access over time, including allowing prescriptions to be issued through telemedicine and mailed to patients under separate regulations that remain the subject of ongoing legal proceedings.
Since the Supreme Court's decision ending the federal constitutional right to abortion, access to medication abortion has become a major legal and political issue across the country.
Advocacy Groups Welcome the Decision
The Center for Reproductive Rights, which represents the abortion providers who filed the lawsuit, welcomed the ruling, arguing it reinforces scientific findings supporting the safety and effectiveness of mifepristone.
Supporters of abortion rights contend that restrictions on the medication limit healthcare access, while opponents continue to seek tighter regulations through courts and state legislation.
The case is expected to continue as broader legal challenges surrounding abortion medication remain pending in federal courts.
